Phase II Pilot Study of Oral Dasatinib in Subjects with Higher Risk Myelodysplastic Syndrome (MDS) Who Failed Conventional Therapy

被引：0
|
作者：
Duong, Vu H. [1 ]
Jaglal, Michael V. [1 ]
Zhang, Ling [2 ]
Kale, Vishakha [3 ]
Lancet, Jeffrey E.
Komrokji, Rami S.
List, Alan F. [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hematopathol & Lab Med, Tampa, FL 33612 USA
[3] James A Haley Vet Hosp, Tampa, FL 33612 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：752 / 753
页数：2
相关论文
共 50 条
  • [11] Results of phase II clinical study of lenalidomide in Japanese patients with myelodysplastic syndrome (MDS)
    Harada, H.
    Watanabe, M.
    Suzuki, K.
    Yanagita, S.
    Suzuki, T.
    Yoshida, Y.
    Kimura, A.
    Tsudo, M.
    Takatoku, M.
    Ozawa, K.
    LEUKEMIA RESEARCH, 2009, 33 : S123 - S123
  • [12] Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).
    Garcia-Manero, Guillermo
    Tambaro, Francesco Paolo
    Bekele, B. Nebiyou
    Jabbour, Elias
    Ravandi, Farhad
    Yang, Hui
    Borthakur, Gautam
    Kadia, Tapan
    Cortes, Jorge
    Faderl, Stefan
    Konopleva, Marina
    Pierce, Sherry
    Burger, Jan A.
    Estrov, Zeev
    O'Brien, Susan
    Thomas, Deborah
    Newsome, Willie
    Kantarjian, Hagop
    BLOOD, 2009, 114 (22) : 436 - 436
  • [13] Phase II Study of Oral Rigosertib Combined With Azacitidine as First-Line Therapy in Patients With Higher-Risk Myelodysplastic Syndromes
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02)
  • [14] Addition of the SMO Inhibitor Sonidegib to Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome (MDS) Who Failed to Respond or Lost Response to AZA Alone: Results of a Phase 1-2 Add-on Study By the GFM
    Vey, Norbert
    BLOOD, 2018, 132
  • [15] A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Wilhelm, Francois
    Hearn, Katherine
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Azarnia, Nozar
    Silverman, Lewis R.
    BLOOD, 2014, 124 (21)
  • [16] A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
    DiNardo, Courtney D.
    Daver, Naval
    Jabbour, Elias
    Kadia, Tapan
    Borthakur, Gautam
    Konopleva, Marina
    Pemmaraju, Naveen
    Yang, Hui
    Wei, Yue
    Wierda, William G.
    Bueso-Ramos, Carlos E.
    Patel, Keyur P.
    Cortes, Jorge E.
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
  • [17] A Phase II Study of Valproic Acid and Lenalidomide Combination Therapy in Patients with Myelodysplastic Syndrome (MDS) and a Favorable Risk Profile: Final Results of the Valena Trial
    Kuendgen, Andrea
    Luebert, Michael
    Schlenk, Richard F.
    Platzbecker, Uwe
    Haase, Detlef
    Haferlach, Torsten
    Schnittger, Susanne
    Giagounidis, Aristoteles
    Brings, Carolin
    Germing, Ulrich
    Haas, Rainer
    Gattermann, Norbert
    BLOOD, 2014, 124 (21)
  • [18] Pilot study of lovastatin in patients with myelodysplastic syndrome (MDS) receiving arsenic trioxide (Trisenox®) therapy.
    Stroh, A
    Carter, TH
    Hohl, RJ
    Zehr, P
    Ritchie, JM
    BLOOD, 2005, 106 (11) : 312B - 312B
  • [19] Phase II study of the histone deacetylase (HDAC) inhibitor belinostat for the treatment of myelodysplastic syndrome (MDS).
    Cashen, A. F.
    Juckett, A.
    Jumonville, A.
    Litzow, M. R.
    Flynn, P. J.
    Eckardt, J. R.
    LaPlant, B.
    Laumann, K. M.
    Erlichman, C.
    DiPersio, J. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [20] A Phase I Pilot Study of Bystander Vaccine and Lenalidomide Immune Augmentation In Patients with Myelodysplastic Syndrome (MDS)
    Padron, Eric
    Komrokji, Rami S.
    Lancet, Jeffrey E.
    List, Alan F.
    Dessureault, Sophie
    Antonia, Scott
    Ahmed, Jamil
    Patel, Shiddhi
    Powers, John
    Bai, Fanqi
    Sotomayor, Eduardo M.
    Epling-Burnette, P. K.
    Pinilla-Ibarz, Javier
    BLOOD, 2010, 116 (21) : 1205 - 1205
12345